Stephane Paul1,2,3, Nicolas Williet4, Thomas Di Bernado4, Anne-Emmanuelle Berger1,2,3, Gilles Boschetti2,5, Jerome Filippi6, Emilie Del Tedesco4, Stephane Nancey2,5, Bernard Flourie2,5, Xavier Roblin2,3,4. 1. Department of Immunology, University Hospital of Saint-Etienne, Saint Etienne, France. 2. INSERM U1111, CIRI, Lyon, France. 3. Groupe Immunité des Muqueuses et Agents Pathogènes [GIMAP], Faculty of Medicine of Saint-Etienne, Saint Etienne, France. 4. Department of Gastroenterology, University Hospital of Saint-Etienne, Saint Etienne, France. 5. Department of Gastroenterology, Lyon Sud Hospital, University Claude Bernard Lyon 1 and Civic Hospices of Lyon, Pierre Benite, France. 6. Department of Gastroenterology, University Hospital of Nice, Nice, France.
Abstract
BACKGROUND AND AIMS: Vedolizumab [VDZ], a humanized monoclonal antibody targeting α4β7 integrin, is effective in induction and maintenance therapy in patients with inflammatory bowel disease [IBD] who have not adequately responded to standard therapies, and high vedolizumab trough levels [VTLs] have been associated with clinical remission. The α4β7 integrin binds to endothelial MAdCAM-1 and is upregulated by retinoic acid [RA]. The aim of this study was to determine the relationships between soluble MAdCAM-1 [sMAdCAM-1] and RA concentrations during clinical remission with VDZ maintenance therapy. METHODS: In a retrospective study performed in IBD patients treated with VDZ, we measured VTL, sMAdCAM-1 and RA concentrations. RESULTS: Among the 62 included patients [38 Crohn's disease], 24 relapsed and 38 stayed in remission from Weeks 10 to 30 after VDZ initiation. During this maintenance therapy, the median values of VTLs and RA were 15.4 µg/mL and 0.97 ng/mL, respectively, whereas sMAdCAM-1 was undetectable [<0.41 ng/mL] in 67.3% of samples. The positive predictive value [PPV] of undetectable sMAdCAM-1 for clinical remission was 80.0%, with a corresponding sensitivity of 74.6%. On multivariate analysis, undetectable sMAdCAM-1 and high VTLs [>19 µg/mL] were independently associated with clinical remission [OR = 7.5, p = 0.006 and OR = 2.2, p = 0.045, respectively]. The combination of sMAdCAM-1 < 0.41 ng/mL and VTL > 19 µg/mL was the best pharmacokinetic profile, with a PPV of 95.2%. Median values of sMAdCAM-1 and RA were significantly higher [p = 0.0001] before VDZ therapy than during the follow-up [sMAdCAM-1: 40.5 vs < 0.41 ng/mL; RA: 1.7 vs 0.97 ng/mL]. Only RA > 1.86 ng/mL before VDZ therapy was predictive of clinical remission during the follow-up (Area Under a Receiver Operating Characteristic curve [AUROC] = 80.7%). CONCLUSIONS: Undetectable sMAdCAM-1 appears strongly associated with clinical remission during VDZ maintenance therapy. Combination of undetectable sMAdCAM-1 with high VTL is also potentially interesting for therapeutic drug monitoring. Baseline RA concentrations are predictive of clinical remission. These findings need to be confirmed in further prospective studies.
BACKGROUND AND AIMS: Vedolizumab [VDZ], a humanized monoclonal antibody targeting α4β7 integrin, is effective in induction and maintenance therapy in patients with inflammatory bowel disease [IBD] who have not adequately responded to standard therapies, and high vedolizumab trough levels [VTLs] have been associated with clinical remission. The α4β7 integrin binds to endothelial MAdCAM-1 and is upregulated by retinoic acid [RA]. The aim of this study was to determine the relationships between soluble MAdCAM-1 [sMAdCAM-1] and RA concentrations during clinical remission with VDZ maintenance therapy. METHODS: In a retrospective study performed in IBDpatients treated with VDZ, we measured VTL, sMAdCAM-1 and RA concentrations. RESULTS: Among the 62 included patients [38 Crohn's disease], 24 relapsed and 38 stayed in remission from Weeks 10 to 30 after VDZ initiation. During this maintenance therapy, the median values of VTLs and RA were 15.4 µg/mL and 0.97 ng/mL, respectively, whereas sMAdCAM-1 was undetectable [<0.41 ng/mL] in 67.3% of samples. The positive predictive value [PPV] of undetectable sMAdCAM-1 for clinical remission was 80.0%, with a corresponding sensitivity of 74.6%. On multivariate analysis, undetectable sMAdCAM-1 and high VTLs [>19 µg/mL] were independently associated with clinical remission [OR = 7.5, p = 0.006 and OR = 2.2, p = 0.045, respectively]. The combination of sMAdCAM-1 < 0.41 ng/mL and VTL > 19 µg/mL was the best pharmacokinetic profile, with a PPV of 95.2%. Median values of sMAdCAM-1 and RA were significantly higher [p = 0.0001] before VDZ therapy than during the follow-up [sMAdCAM-1: 40.5 vs < 0.41 ng/mL; RA: 1.7 vs 0.97 ng/mL]. Only RA > 1.86 ng/mL before VDZ therapy was predictive of clinical remission during the follow-up (Area Under a Receiver Operating Characteristic curve [AUROC] = 80.7%). CONCLUSIONS: Undetectable sMAdCAM-1 appears strongly associated with clinical remission during VDZ maintenance therapy. Combination of undetectable sMAdCAM-1 with high VTL is also potentially interesting for therapeutic drug monitoring. Baseline RA concentrations are predictive of clinical remission. These findings need to be confirmed in further prospective studies.
Authors: Robert Battat; Parambir S Dulai; Niels Vande Casteele; Elisabeth Evans; Kelly D Hester; Edvelyn Webster; Anjali Jain; James A Proudfoot; Ara Mairalles; Jennifer Neill; Siddharth Singh; John T Chang; Jesus Rivera-Nieves; William J Sandborn; Brigid S Boland Journal: Inflamm Bowel Dis Date: 2019-01-10 Impact factor: 5.325
Authors: Cara De Galan; Gerard Bryan Gonzales; Sophie Van Welden; Simon Jan Tavernier; Triana Lobaton; Wouter Van Moerkercke; Beatrijs Strubbe; Harald Peeters; Elisabeth Macken; Martine De Vos; Debby Laukens; Pieter Hindryckx Journal: Clin Transl Med Date: 2022-04
Authors: Ariela K Holmer; Robert Battat; Parambir S Dulai; Niels Vande Casteele; Nghia Nguyen; Anjali Jain; Ara Miralles; Jennifer Neill; Helen Le; Siddharth Singh; Jesus Rivera-Nieves; William J Sandborn; Brigid S Boland Journal: Therap Adv Gastroenterol Date: 2020-11-12 Impact factor: 4.409
Authors: Renske Wilhelmina Maria Pauwels; Annemarie Charlotte de Vries; Christien Janneke van der Woude Journal: J Gastroenterol Hepatol Date: 2020-05-04 Impact factor: 4.029